Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Atai Life Sciences N.V. (ATAI)

Atai Life Sciences N.V. (ATAI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 752,230
  • Shares Outstanding, K 160,733
  • Annual Sales, $ 20,380 K
  • Annual Income, $ -167,810 K
  • 60-Month Beta 0.63
  • Price/Sales 34.79
  • Price/Cash Flow N/A
  • Price/Book 2.00
Trade ATAI with:

Options Overview Details

View History
  • Implied Volatility 122.73% ( -2.16%)
  • Historical Volatility 65.58%
  • IV Percentile 85%
  • IV Rank 34.16%
  • IV High 240.23% on 05/13/22
  • IV Low 61.77% on 10/08/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 421
  • Volume Avg (30-Day) 184
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 11,341
  • Open Int (30-Day) 10,568

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.23
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +29.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.51 +26.21%
on 08/02/22
4.86 -8.85%
on 08/08/22
+0.21 (+4.98%)
since 07/11/22
3-Month
2.95 +50.17%
on 06/14/22
4.86 -8.85%
on 08/08/22
+1.30 (+41.53%)
since 05/11/22
52-Week
2.95 +50.17%
on 06/14/22
17.90 -75.25%
on 09/08/21
-9.52 (-68.24%)
since 08/11/21

Most Recent Stories

More News
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant...

MMED.NE : 0.800 (-4.76%)
CYBN.NE : 1.090 (+0.93%)
OPTI.CN : 0.380 (-3.80%)
OPTHF : 0.3118 (+4.46%)
ATAI : 4.43 (-5.34%)
MNMD : 0.6503 (-0.21%)
CYBN : 0.8566 (+0.78%)
ENVB : 6.78 (+5.12%)
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

/PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of...

OPTI.CN : 0.380 (-3.80%)
OPTHF : 0.3118 (+4.46%)
ATAI : 4.43 (-5.34%)
MNMD : 0.6503 (-0.21%)
CYBN : 0.8566 (+0.78%)
ENVB : 6.78 (+5.12%)
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming...

ATAI : 4.43 (-5.34%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...

CYBN.NE : 1.090 (+0.93%)
SILO : 0.1392 (-7.14%)
FTRP : 0.8500 (+0.58%)
FTRP.TO : 1.10 (unch)
ATAI : 4.43 (-5.34%)
CYBN : 0.8566 (+0.78%)
ENBI.CN : 0.085 (+13.33%)
ENTBF : 0.0700 (+35.40%)
CMPS : 17.33 (-12.16%)
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

/PRNewswire/ -- For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many...

ENTBF : 0.0700 (+35.40%)
FTRP.TO : 1.10 (unch)
SILO : 0.1392 (-7.14%)
FTRP : 0.8500 (+0.58%)
ATAI : 4.43 (-5.34%)
CYBN : 0.8566 (+0.78%)
CMPS : 17.33 (-12.16%)
New Regulations for Psychedelics? Here's What Investors Need to Know

There are a couple of proposed regulations and policies in the pipeline.

ATAI : 4.43 (-5.34%)
COMP : 4.65 (-1.90%)
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Dr. Chad Beyer will join as CEO on July 1, 2022...

ATAI : 4.43 (-5.34%)
Stephen Bardin to Join atai Life Sciences as CFO Designate

Stephen Bardin will join as CFO Designate on June 27, 2022After a transition period, atai’s current CFO Greg Weaver will be moving into a part time...

ATAI : 4.43 (-5.34%)
BBIO : 10.88 (-9.26%)
atai Life Sciences to Participate in Upcoming June Healthcare Conferences

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming...

ATAI : 4.43 (-5.34%)
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision...

ATAI : 4.43 (-5.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.

See More

Key Turning Points

3rd Resistance Point 5.03
2nd Resistance Point 4.89
1st Resistance Point 4.66
Last Price 4.43
1st Support Level 4.29
2nd Support Level 4.15
3rd Support Level 3.92

See More

52-Week High 17.90
Fibonacci 61.8% 12.19
Fibonacci 50% 10.43
Fibonacci 38.2% 8.66
Last Price 4.43
52-Week Low 2.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar